All In Biotech

Drug Trial Radar · NCT00425555

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Aug 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

139

Actual

Start

Jan 2007

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.

Conditions

  • Cutaneous T-Cell Lymphoma

Interventions

  • PanobinostatDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate of Participants Using the Modified Severity-Weighted Assessment Tool (mSWAT)Time frame: Baseline up to 6 Months of Follow up

Locations

42 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham/ Kirklin Clinic Kirklin Clinic

    Birmingham, Alabama

  • City of Hope National Medical Center

    Duarte, California

  • University of California at Los Angeles Dept. of Hematology-Oncology

    Los Angeles, California

  • Florida Academic Dermatology Center

    Miami, Florida

  • Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2)

    Atlanta, Georgia

  • Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia

    Augusta, Georgia

  • NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept. of NorthwesterUMed

    Chicago, Illinois

  • Indiana University Dept. of IU Cancer Center

    Indianapolis, Indiana

  • Boston Medical Center StudyCoordinator:CLBH589B2201

    Boston, Massachusetts

  • Dana Farber Cancer Institute Deptof DanaFarberCancerInst(3)

    Boston, Massachusetts

  • University of Michigan Health System Michigan HouseClinTrialsOffice

    Ann Arbor, Michigan

  • Wake Forest University Baptist Medical Center OutpatientCmprehensivCancerCtr

    Winston-Salem, North Carolina

  • University Dermatology Consultants

    Cincinnati, Ohio

  • Oregon Health & Science University Dept. of OHSU Cancer Institute

    Portland, Oregon

  • University of Pittsburgh Medical Center Department of Dermatology

    Pittsburgh, Pennsylvania

  • MD Anderson Cancer Center/University of Texas StudyCoordinator:CLBH589B2201

    Houston, Texas

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    South Brisbane, Queensland, Australia

  • Novartis Investigative Site

    Parkville, Victoria, Australia

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Yvoir, Belgium

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Lyon, Cedex 02, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Minden, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Ancona, AN, Italy

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.